Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Systematic Analysis of Icotinib Treatment for Patients with Non-Small Cell Lung Cancer

  • Shi, Bing (Department of Oncology, The Second Hospital of Nantong City) ;
  • Zhang, Xiu-Bing (Department of Oncology, The Second Hospital of Nantong City) ;
  • Xu, Jian (Department of Oncology, The Second Hospital of Nantong City) ;
  • Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research)
  • Published : 2015.08.03
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: This analysis was conducted to evaluate the efficacy and safety of icotinib based regimens in treating patients with non-small cell lung cancer (NSCLC). Methods: Clinical studies evaluating the efficacy and safety of icotinib-based regimens with regard to response and safety for patients with NSCLC were identified using a predefined search strategy. Pooled response rates of treatment were calculated. Results: With icotinib-based regimens, 7 clinical studies which including 5,985 Chinese patients with NSCLC were considered eligible for inclusion. The pooled analysis suggested that, in all patients, the positive reponse rate was 30.1% (1,803/5,985) with icotinib-based regimens. Mild skin itching, rashes and diarrhea were the main side effects. No grade III or IV renal or liver toxicity was observed. No treatment-related death occurred in patients treated with icotinib-based regimens. Conclusions: This evidence based analysis suggests that icotinib based regimens are associated with mild response rate and acceptable toxicity for treating Chinese patients with NSCLC.

Keywords

References

  1. Cappuzzo F, Ciuleanu T, Stelmakh L, et al (2010). Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol, 11, 521-9. https://doi.org/10.1016/S1470-2045(10)70112-1
  2. Chen X, Zhu Q, Liu Y, et al (2014). Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study. PLoS One, 9, 95897. https://doi.org/10.1371/journal.pone.0095897
  3. Ellis PM, Blais N, Soulieres D, et al (2011). A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol, 6, 1379-91. https://doi.org/10.1097/JTO.0b013e318220cb8e
  4. Feld R, Sridhar SS, Shepherd FA, et al (2006). Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review. J Thorac Oncol, 1, 367-76. https://doi.org/10.1097/01243894-200605000-00018
  5. Fossella FV, DeVore R, Kerr RN, et al (2000). Randomized phase iii trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The tax 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol, 18, 2354-62.
  6. Fukuoka M, Yano S, Giaccone G, et al (2003). Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol, 21, 2237-46. https://doi.org/10.1200/JCO.2003.10.038
  7. Govindan R, Page N, Morgensztern D, et al. (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 24, 4539-44 https://doi.org/10.1200/JCO.2005.04.4859
  8. Gridelli C, Ciardiello F, Gallo C, et al (2012). First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol, 30, 3002-11. https://doi.org/10.1200/JCO.2011.41.2056
  9. Hanna N, Shepherd FA, Fossella FV, et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 22, 1589-97. https://doi.org/10.1200/JCO.2004.08.163
  10. Hotta K, Fujiwara Y, Kiura K, et al (2007) Relationship between response and survival in more than 50, 000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thorac Oncol, 2, 402-7. https://doi.org/10.1097/01.JTO.0000268673.95119.c7
  11. Hu X, Han B, Gu A, et al (2014). A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC). Lung Cancer, 86, 207-12. https://doi.org/10.1016/j.lungcan.2014.08.014
  12. Jemal A, Bray F, Center MM, et al (2011) Global cancer statistics. CA Cancer J Clin, 61, 69-90 https://doi.org/10.3322/caac.20107
  13. Leighl NB (2012). Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Curr Oncol, 19, 52-8.
  14. Liu D, Jiang J, Hu P, et al (2009). Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 877, 3781-6. https://doi.org/10.1016/j.jchromb.2009.08.055
  15. Lynch TJ, Bell DW, Sordella R, et al (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350, 2129-39. https://doi.org/10.1056/NEJMoa040938
  16. National Comprehensive Cancer Network. Non Small Cell Lung Cancer. 2013, cited 2013-10-30. Available from: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
  17. Paez JG, Janne PA, Lee JC, et al (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-500. https://doi.org/10.1126/science.1099314
  18. Pan H, Liu R, Li S, et al (2014). Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes. Cell Biochem Biophys, 70, 553-8. https://doi.org/10.1007/s12013-014-9955-y
  19. Ramalingam SS, Dahlberg SE, Langer CJ, et al. (2008) Outcomes for elderly, advanced-stage non-small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol, 26, 60-5. https://doi.org/10.1200/JCO.2007.13.1144
  20. Scagliotti GV, Parikh P, von Pawel J, et al (2008). Phase iii study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small-cell lung cancer. J Clin Oncol, 26, 3543-51. https://doi.org/10.1200/JCO.2007.15.0375
  21. Schiller JH, Harrington D, Belani CP, et al (2002). On behalf of the eastern cooperative oncology group comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8. https://doi.org/10.1056/NEJMoa011954
  22. Shao L, Zhang B, He C, et al (2014). Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancerafter failure of chemotherapy. Chin Med J (Engl), 127, 266-71.
  23. Shepherd FA, Dancey J, Ramlau R, et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 18, 2095-103.
  24. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 353, 123-32. https://doi.org/10.1056/NEJMoa050753
  25. Soda M, Choi YL, Enomoto M, et al (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448, 561-6. https://doi.org/10.1038/nature05945
  26. Tan F, Shen X, Wang D, et al (2012). Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer, 76, 177-182. https://doi.org/10.1016/j.lungcan.2011.10.023
  27. Kris MG, Natale RB, Herbst RS, et al (2003). Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 290, 2149-2158. https://doi.org/10.1001/jama.290.16.2149
  28. Yang X, Zhang H, Qin N, et al (2013). Clinical observation of icotinib hydrochloride in first-line therapy for pulmonary adenocarcinoma. Zhongguo Fei Ai Za Zhi, 16, 364-8.
  29. Zhao Q, Shentu J, Xu N, et al (2011). Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer, 73, 195-202. https://doi.org/10.1016/j.lungcan.2010.11.007
  30. Zheng X, Liu G, Wang S, et al (2014). A new receptor tyrosine kinase inhibitor, icotinib, for patients with lung adenocarcinomacancer without indication for chemotherapy. Oncol Lett, 8, 1563-6.
  31. Zheng Y, Fang W, Deng J, et al (2014). Sequential treatment of icotinib after first-line pemetrexed in advanced lungadenocarcinoma with unknown EGFR gene status. J Thorac Dis, 6, 958-64.

Cited by

  1. Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.413
  2. A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.485